The global digital diabetes management market, valued at USD 11.8 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 8.3% from 2023 to 2030. The rapid growth in this sector is primarily driven by the increasing global prevalence of diabetes and the continuous advancements in digital technology. According to the International Diabetes Federation, 537 million adults were affected by diabetes in 2021, with this number projected to rise to 783 million by 2045. This trend emphasizes the need for innovative solutions to effectively manage diabetes, fueling the market for digital diabetes management tools. Recently, the number of smartphone applications designed to monitor blood glucose levels has grown substantially, with over a hundred available on various app platforms, enabling individuals to manage their condition more effectively.

Diabetes is a chronic condition characterized by the pancreas's inability to produce sufficient insulin, leading to elevated blood glucose levels. Diabetic individuals encounter daily challenges, such as determining suitable food choices, comprehending medical guidance, and understanding how activities impact their blood sugar levels. Digital technology's portability and accessibility allow patients to address these concerns in real time, often from anywhere, while facilitating communication with healthcare professionals and enabling data sharing. This digital connectivity fosters a comprehensive ecosystem where data-driven solutions support more effective diabetes management.

Gather more insights about the market drivers, restrains and growth of the Digital Diabetes Management Market

Regional Insights:

North America Digital Diabetes Management Market Trends

In 2022, North America led the digital diabetes management market, with over 38% of total revenue, benefiting from the availability of cutting-edge technology and regulatory approvals for innovative diabetes management devices. For example, in January 2022, Insulet Corporation received FDA clearance for its Omnipod 5 Automated Insulin Delivery System, which works with the Dexcom G6 Continuous Glucose Monitor (CGM). This device allows for remote patient monitoring and data transfer via the Omnipod 5 mobile app, which includes an integrated SmartBolus Calculator. The growing elderly population and increasing prevalence of diabetes, partly due to lifestyle-related factors, are expected to continue driving market growth in the region.

Asia Pacific Digital Diabetes Management Market Trends

The Asia Pacific region is anticipated to have the highest growth rate, with a CAGR of 9.8% during the forecast period. This growth is attributed to the region's large diabetic population, numerous product launches, and rising government initiatives to address diabetes. In January 2022, for instance, the Australian Centre for Accelerating Diabetes Innovations (ACADI) at the University of Melbourne received a USD 10 million grant from the federal government for diabetes-related research and innovation over four years. ACADI, a virtual research center, aims to connect researchers across Australia to collaborate with industry and develop new therapies, technologies, and behavior-based interventions for diabetes management.

Browse through Grand View Research's Category Medical Devices Industry Research Reports.

• The global maggot debridement market size was valued at USD 14.3 million in 2024 and is anticipated to grow at a CAGR of 10.3% from 2025 to 2030.
• The global neurothrombectomy devices market size was estimated at USD 739.81 million in 2024 and is anticipated to grow at a CAGR of 6.94% from 2025 to 2030.

Key Companies & Market Share Insights:

Leading companies in the digital diabetes management market are focused on integrating advanced technologies, launching new products, forming strategic partnerships, and leveraging government initiatives to enhance their services and increase market presence. For example, in August 2022, Abbott Laboratories partnered with WeightWatchers to introduce digital tools that emphasize weight management and blood sugar control for diabetes patients. As part of this collaboration, Abbott’s glucose monitoring technology was integrated into WeightWatchers' diabetes-focused program, allowing patients to better track their health.

Another key development came in May 2021 when Ascensia Diabetes Care introduced GlucoContro.online, a browser-based platform offering analytics and data-driven diabetes management for users of CONTOUR blood glucose monitoring meters. Similarly, in September 2021, Ypsomed AG partnered with Dexcom, a leader in continuous glucose monitoring (CGM) systems, to make data from the Dexcom G6 CGM device available within the Ypsomed mobile application, allowing patients to access glucose data on their smartphones for easier monitoring and management of their condition.

Key Digital Diabetes Management Companies:

• Abbott
• Medtronic
• Hoffmann-La Roche Ltd.
• Bayer AG
• Sanofi
• Dexcom, Inc.
• LifeScan, Inc.
• Insulet Corporation
• Ascensia Diabetes Care Holdings AG
• Braun Melsungen AG

Order a free sample PDF of the Digital Diabetes Management Market Intelligence Study, published by Grand View Research.